Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

RCSB Protein Data Bank Launches Mobile Application

October 3, 2014 – 2:48 pm | Edit Post

The RCSB Protein Data Bank (PDB), which recently archived its 100,000th molecule structure, has introduced a free mobile application device that enables users from the general public and expert researchers to quickly search and visualize the 3D shapes of proteins, nucleic acids, and molecular machines.

RCSB Protein Data Bank Launches Mobile Application

October 3, 2014 – 2:48 pm | Edit Post

The RCSB Protein Data Bank (PDB), which recently archived its 100,000th molecule structure, has introduced a free mobile application device that enables users from the general public and expert researchers to quickly search and visualize the 3D shapes of proteins, nucleic acids, and molecular machines.

Sorrento and Lee’s Pharmaceutical Enter into Exclusive China Licensing Agreement to Develop and Commercialize Anti-PD-L1 antibody

October 3, 2014 – 11:41 am | Edit Post

SAN DIEGO, Oct. 3, 2014 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that China Oncology Focus Limited, an Affiliate of Lee’s Pharmaceutical Holdings Limited (Lee’s Pharma), a public biopharmaceutical company listed on the main board of Hong Kong Stock Exchange (0950) with over 20 years of operation in China’s pharmaceutical industry, has licensed Sorrento’s fully human immune-oncology anti-PD-L1 monoclonal antibody (mAb) STI-A1014.

San Diego Life Sciences Roundup: Ambit, Zogenix, Aethlon, and More

October 3, 2014 – 6:40 am | Edit Post

Assessing the extent of long-term brain damage from concussions in football and other impact sports can be difficult (to say the least) if the only way to determine whether an individual is suffering…

[[Click headline to continue reading.]]

Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study

October 2, 2014 – 1:02 pm | Edit Post

SAN DIEGO, Oct. 2, 2014 /PRNewswire/ — Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a clinical trial of NBI-98854, a proprietary small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in both children and adolescents with Tourette syndrome.

2014 Pedal the Cause San Diego was a phenomenal success

October 2, 2014 – 12:01 pm | Edit Post

Team Sanford-Burnham, along with more than 750 riders, crossed the finish line to thundering applause and enthusiastic cheers on Sept. 21 as the second annual Pedal the Cause San Diego bike event came to a successful end.

Convocation Keynote Encourages Students to Recognize Power They Have to Influence Others

October 2, 2014 – 6:00 am | Edit Post

Mahatma Gandhi had a saying that he used to mobilize millions of poor people in India to gain independence: “You must be the change you wish to see in the world.”

Diabetes in a Dish

October 1, 2014 – 2:27 pm | Edit Post

Researchers at University of California, San Diego School of Medicine are co-recipients of a $4.1-million grant from the National Institutes of Health to advance treatments for type 1 diabetes. Using human stem cells, the team plans to culture bits of human pancreas in a dish and, using microfluidics, mimic blood flow through the islet.

Health Care and Construction Workers Create Pink Ribbon For Breast Cancer Awareness

September 30, 2014 – 1:55 pm | Edit Post

More than 600 health care and construction workers donned pink hard hats while forming a giant human ribbon at the UC San Diego Jacobs Medical Center construction site today in support of National Breast Cancer Awareness month.

Phase III Clinical Trial to Evaluate Calcium Channel Blocker for Parkinson’s

September 30, 2014 – 10:36 am | Edit Post

Phase III Clinical Trial to Evaluate Calcium Channel Blocker for Parkinson’s

Researchers at the University of California, San Diego School of Medicine have launched a Phase III clinical trial to evaluate the drug isradipine, a calcium channel blocker often used to treat high blood pressure, as a potential new treatment for Parkinson disease. The goal of the study is to determine whether the drug can slow the progression of the disease by keeping the brain’s dopamine-producing cells healthier for a longer period of time.